Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals shows a slight decrease today, losing -€0.140 (-0.670%) compared to yesterday.
The stock is one of the favorites of our community with 32 Buy predictions and 1 Sell predictions.
With a target price of 27 € there is a positive potential of 31.58% for Acadia Pharmaceuticals compared to the current price of 20.52 €.
Our community identified positive and negative aspects for Acadia Pharmaceuticals stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acadia Pharmaceuticals stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | -0.670% | -4.380% | -8.556% | 14.032% | -11.666% | 19.958% | -49.994% |
| Ironwood Pharmaceuticals | -1.590% | 0.000% | 9.945% | 93.204% | 49.624% | -62.059% | -53.176% |
| Novocure Ltd | -1.630% | -6.977% | -12.383% | -56.999% | -13.542% | -88.765% | -93.301% |
| Iovance Biotherapeutics Inc. | -6.440% | -10.557% | -3.890% | -63.095% | -13.027% | -72.114% | -94.924% |
Comments
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat